Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

The user experienced significant hair regrowth on temples and beard using a combination of Dutasteride, Tretinoin, and topical Minoxidil, but stopped oral Minoxidil due to heart pain. The user switched from Finasteride to Dutasteride due to aggressive hair loss.

A user has been experiencing hair loss for 4 years, with treatments like minoxidil, finasteride, and various supplements proving ineffective. They were diagnosed with fibrosing alopecia in a pattern distribution, a condition that may require a combination of anti-inflammatory and hair growth treatments.

The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.

A 36-year-old experienced significant hair regrowth using minoxidil, finasteride, and tretinoin with minimal side effects. He plans to continue the treatment, hoping for more targeted solutions in the future.

Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.

A user's progress in treating their hair loss with finasteride, minoxidil and oral minoxidil, as well as microneedling. Replies to the post have encouraged the user that they are seeing regrowth from the treatments.

The conversation discusses the importance of taking vitamin D with food for better absorption and its potential role in hair loss. Some users also suggest taking vitamin D with K2, getting sunlight, and using finasteride for hair loss treatment.

The conversation discusses hair loss treatments including finasteride, minoxidil, derma rolling, and tretinoin, with the user showing progress after five months. Tretinoin is mentioned to enhance the effectiveness of minoxidil.

A 28-year-old male is experiencing temple regrowth but crown thinning while using 5mg minoxidil and 0.5mg dutasteride. The shedding phase is seen as a positive sign of treatment effectiveness, with expectations of noticeable improvements around 6 to 12 months.

The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.

A woman experienced hair regrowth after using self-prescribed finasteride and dutasteride from online sources, despite doctors' reluctance to prescribe these due to potential birth defects. Her dermatologist acknowledged the effectiveness of these treatments and advised her to continue using them while avoiding pregnancy.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

The user shared a 4-5 month update on using finasteride, minoxidil, vitamins, oiling, and microneedling for hair loss. They reported improved hair density and confidence but experienced unwanted hair growth, thin hair, itching, and a flaky scalp.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

The user is questioning if their hair is regrowing and considering adding tretinoin to their regimen, which includes minoxidil. They are concerned about male pattern baldness and comparing their current hairline to past photos.

The user experienced hair regrowth using finasteride, minoxidil, biotin, iron, microneedling, and caffeine shampoo over four months. They plan to continue treatment for fuller results by month 6 or 7.

The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.

The user experienced significant hair regrowth using 5 mg daily oral minoxidil and ketoconazole shampoo, improving from Norwood 3 to Norwood 2. They recommend starting treatment early, noting reduced shedding and stable results.

The user experienced significant hair regrowth after 60 days using a topical compound of Minoxidil, Finasteride, and Tretinoin, along with oral Minoxidil and Finasteride. They reported initial side effects but saw improvement in hair density and appearance.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.

The user has been using finasteride, vitamin D3, and zinc for 5.5 months and had a hair transplant 3.5 months ago, focusing on the hairline and crown. Some users see subtle improvements in hair density, suggesting adding minoxidil for better results.

The user has been using a treatment regimen for hair loss for 8 months, including topical 5% minoxidil, 2.5 mg daily minoxidil, 5 mg finasteride every other day, and vitamins. They shared progress pictures showing little change in the crown area.

User took vitamin D for 6 months and experienced hair regrowth. Others suggest comparing hair at the same length and lighting for accurate results.

The user is using oral Minoxidil, oral Dutasteride, microneedling, and RU58841 for hair loss, noticing slow progress with small hairs appearing. They are inconsistent with microneedling frequency, sometimes doing it weekly or skipping weeks.